$ARTV

Thursday’s insider buys and sells: Artiva, StoneX and CoreWeave By Investing.com

A roundup of SEC-reported insider trades for US-listed firms. RA Capital Management bought about $2.58M of Artiva Biotherapeutics (ARTV). Byrna Technologies (BYRN) saw board chair and CEO buy about $179k and $77k. Aqua Capital bought about 120k Energizer (ENR) shares. StoneX (SNEX) insiders sold about $7.8M, $3.89M, and $7.13M. CoreWeave (CRWV) CEO sold about $24.1M under a 10b5-1 plan; Travelers (TRV) CFO sold about $6.01M.

Original reporting
Published Jul 24, 2026, 1:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 1:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$ARTV
Bullish
medium confidence
Mentioned
$ARTV · $BYRN · $ENR · $SNEX · $CRWV · $TRV
Relevance
4/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$ARTVBullishLow
01

Why it matters

For traders, the actionable signal is mostly sentiment and positioning around recent lows or highs, not a new operational catalyst. The most tradable angle is short-term reaction to unusual clustering of buys (BYRN) versus large sales (CRWV, SNEX) when markets are already sensitive to momentum.

02

Market read

This is a sentiment/positioning read-through from insider transactions, with limited fundamental implications because it lacks earnings, guidance, contracts, or regulatory actions.

03

What to watch

The article does not confirm whether transactions were under 10b5-1 for all parties, nor does it provide post-transaction holdings beyond the described direct/indirect shares, limiting inference quality.

Relevance 4/10Novelty 3/10Timing: insider Form 4 activity disclosed for trades dated July 21-23, 2026

Background

The piece is a roundup of disclosed insider trading activity for multiple US-listed companies, citing SEC filing details and transaction sizes/prices.

Company-level read

Ticker impact

$ARTVBullishMedium confidence
Context

RA Capital Management bought about $2.58M of Artiva Biotherapeutics shares over three days, signaling fresh insider/major-holder positioning.

Expected impact

Mildly positive bias for the next few sessions, with follow-through dependent on broader tape and fundamentals.

Evidence & confidence

The article provides transaction size and timing, but insider buys alone rarely drive sustained repricing without accompanying company-specific news.

$BYRNBullishMedium confidence
Context

Byrna Technologies saw both the board chairman and CEO buy shares near the 52-week low, totaling about $179k across July 22-23.

Expected impact

Short-term upside skew, but likely limited without additional operational catalysts.

Evidence & confidence

The text includes specific buy dates, share counts, and prices, but does not provide new business developments or earnings changes.

$ENRBullishMedium confidence
Context

Aqua Capital, a 10% owner and director, bought 120,000 Energizer Holdings shares over July 21-22 for roughly $2.43M.

Expected impact

Slightly positive near-term, with volatility tied to ENR fundamentals rather than the transaction itself.

Evidence & confidence

The article gives concrete purchase details, but insider/owner buys are not equivalent to new guidance or contract wins.

$SNEXNeutralMedium confidence
Context

StoneX insiders sold sizable blocks after option exercises, including about $7.8M by the executive vice-chairman and about $3.89M by the chief risk officer.

Expected impact

Neutral to mildly negative for sentiment, with limited directional edge absent other catalysts.

Evidence & confidence

The article provides transaction values and roles, but does not indicate distress, regulatory action, or new negative fundamentals.

$CRWVNeutralMedium confidence
Context

CoreWeave CEO/President sold about 303,692 shares for roughly $24.07M under a Rule 10b5-1 plan on July 21.

Expected impact

Neutral near-term, possibly slight drag if traders interpret it as reduced conviction.

Evidence & confidence

The plan details and sale size are clear, but 10b5-1 sales are often non-informational regarding near-term business outlook.

$TRVNeutralMedium confidence
Context

Travelers CFO sold about $6.01M of shares acquired via option exercises on July 21.

Expected impact

Neutral to mildly negative sentiment effect, likely short-lived.

Evidence & confidence

The article includes specific sale value and share counts, but provides no new company performance or guidance changes.

Market effects

No direct sector catalyst; signals are company-specific insider positioning rather than industry-wide news.

Primarily US-listed names; no cross-market macro linkage in the text.

Limited global relevance, as the article is a US insider-transaction roundup without international deal/regulatory developments.

Counterpoint

Insider buys and sells here may be largely non-informational (option exercises, 10b5-1 plans, diversification), so price impact may be muted versus fundamentals.

Key entities

  • Artiva Biotherapeutics

    Major shareholder RA Capital bought additional shares totaling about $2.58M over three days.

  • Byrna Technologies

    Board chairman and CEO bought shares totaling about $179k near the 52-week low.

  • Energizer Holdings

    10% owner/director Aqua Capital bought 120,000 shares for about $2.43M.

  • StoneX Group

    Multiple executives sold shares worth roughly $7.8M, $3.89M, and $7.13M after option exercises.

  • CoreWeave

    CEO sold about 303,692 shares for about $24.07M under a Rule 10b5-1 plan.

Related articles

$ARTVMed

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 artv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion

$ENRMed

Energizer Holdings, Inc. Q3 2026 Earnings Call Summary

Energizer Holdings reported organic growth in Batteries & Lights and Auto Care despite a softer battery category. Management revised fiscal 2026 back-half outlook to roughly flat to up 1% organic growth, citing 200 to 300 bps category softening. Q4 gross margins are projected above 40% and adjusted EPS to rise 25% at the midpoint, with capex near 1% of net sales and free cash flow improving as Project Momentum ends.

$SNEXMedAI 8/10

StoneX Group Inc. (SNEX): Results of Operations and Financial Condition

StoneX Group Inc. (SNEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 snex2026er_exhq3roll.htm EX-99.1 Document EXHIBIT 99.1 StoneX Group Inc. Reports Fiscal 2026 Third Quarter Financial Results Quarterly Net Operating Revenues of $719.7 million, up 47% Quarterly Net Income of $127.9 million, Quarterly ROE of 18.4% Quarterly Diluted EPS o